SITRA
24.10.2016 14:49:39 CEST | Business Wire | Press release
The world is in serious need of solutions concerning how to sustainably create growth and jobs. A pioneering event will offer those solutions in June 2017 in Helsinki, Finland. The agenda features the world’s best circular economy solutions based on the implementation of the UN’s Sustainable Development Goals. The event is organised by Sitra together with a large group of global institutions.
Sitra is inviting the future shapers of our well-being to celebrate Finland’s 100th year of independence at the World Circular Economy Forum 2017 in Helsinki. The event (5-6 June 2017) brings together 1,200 international business and NGO leaders, managers, urban experts and government officials.
The focus of the event is on genuinely sustainable and competitive solutions for the circular economy – on solutions that have been created in different parts of the world and in which business and the environment go hand in hand. The circular economy plays an important role in the realisation of the UN’s Sustainable Development Goals.
”We will also explain how Finland, as the first country in the world, is implementing its national roadmap of the circular economy – how the whole society is increasing its competitiveness and benefiting from moving to a new operational model for the economy, a model in which the growth of the economy and well-being are no longer based on the overconsumption of natural resources and fossil fuels”, says Mari Pantsar , the director resource-wise and carbon-neutral activities in Sitra.
The group of most recognized speakers presenting diverse solutions for the circular economy at the World Circular Economy Forum covers a large spectrum of the world’s top experts. Among the participants are Achim Steiner , the former head of the UN’s Environment Programme; Jyrki Katainen , EU Commissioner; Ashok Khosla , Founder and President of Development Alternatives and Co-chair of the UN’s International Resource Panel; Janez Potocnik , Co-chair of the UN’s International Resource Panel and Matti Lievonen , Managing director of Neste.
The organisers of the WCEF2017 are Sitra, the Nordic Council of Ministers, the Ministry of the Environment and the Ministry of Economic Affairs and Employment in cooperation with the following institutions: European Commission, European Environment Agency (EEA), International Institute for Sustainable Development (IISD), Koli Forum, United Nations Environment Programme (UNEP), World Business Council for Sustainable Development (WBCSD) and World Resources Forum (WRF).
Website of the event www.wcef2017.com
Sitra is a future fund that collaborates with partners from different sectors to research, trial and implement bold new ideas that shape the future. Our aim is a Finland that succeeds as a pioneer in sustainable well-being.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005743/en/
Contact:
Sitra
Hanna-Leena Ottelin, Specialist
hanna-leena.ottelin(at)sitra.fi
+358
(0)50 376 9499
or
Kari Herlevi, Senior Lead
kari.herlevi(at)sitra.fi
+358
(0)50 463 9397
or
Samuli Laita, Communications
samuli.laita(at)sitra.fi
+358
(0)40 536 8650
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom